journal
MENU ▼
Read by QxMD icon Read
search

Infectious Diseases and Therapy

journal
https://www.readbyqxmd.com/read/28477061/chronic-hepatitis-c-treatment-in-patients-with-drug-injection-history-findings-of-the-integrate-prospective-observational-study
#1
Geert Robaeys, Stefan Christensen, Damien Lucidarme, Amber Arain, Philip Bruggmann, Jan Kunkel, Sofia Keim, Martin Jäkel, Ralph DeMasi, Chris Liu, Isabelle Lonjon-Domanec, Graham R Foster
INTRODUCTION: People who inject drugs represent an under-treated chronic hepatitis C virus (HCV)-infected patient population. METHODS: INTEGRATE was a prospective, observational study investigating the effectiveness, safety, and adherence in routine clinical practice to telaprevir in combination with peg-interferon and ribavirin (Peg-IFN/RBV) in patients with history of injecting drug use chronically infected with genotype 1 HCV. RESULTS: A total of 46 patients were enrolled and included in the intent-to-treat (ITT) population...
May 5, 2017: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/28417331/use-of-high-dose-oral-valacyclovir-during-an-intravenous-acyclovir-shortage-a-retrospective-analysis-of-tolerability-and-drug-shortage-management
#2
Milena M McLaughlin, Sarah H Sutton, Ashley O Jensen, John S Esterly
INTRODUCTION: In late 2011, a shortage of IV acyclovir led to the need to empirically substitute high-dose oral valacyclovir (HDVA) to conserve IV acyclovir for patients with confirmed herpes simplex virus (HSV) meningitis or encephalitis. This report describes the management of the most recent national IV acyclovir shortage by the Antimicrobial Stewardship Program (ASP) at Northwestern Memorial Hospital (NMH), Chicago, IL, USA, and the use of HDVA. Secondarily, we assessed the safety and tolerability of HDVA as an alternate to IV acyclovir during this shortage...
April 17, 2017: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/28386776/real-world-experience-with-oritavancin-therapy-in-invasive-gram-positive-infections
#3
Cassie L Stewart, Michelle S Turner, Jeremy J Frens, Cynthia B Snider, Jordan R Smith
INTRODUCTION: Oritavancin is a novel lipoglycopeptide approved for acute bacterial skin and skin structure infections. The pharmacokinetic profile and convenient one-time dosing make oritavancin an enticing option for other serious Gram-positive infections requiring prolonged treatment courses. Unfortunately, data for using oritavancin in these populations are limited. METHODS: We report ten cases of oritavancin use for invasive Gram-positive infections in our health system, and provide a review of the currently available literature regarding oritavancin therapy for invasive infections...
April 6, 2017: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/28374267/risk-factors-for-and-outcomes-of-multidrug-resistant-escherichia-coli-infections-in-children
#4
Adaora S Uzodi, Christine M Lohse, Ritu Banerjee
INTRODUCTION: The recent increase in multidrug-resistant (MDR) Escherichia coli infections is not well described in children. We determined the risk factors and outcomes of extraintestinal E. coli infections in children in our region. METHODS: We conducted a retrospective cohort study of children ≤18 years in Olmsted County, MN, USA, between January 1, 2012 and December 31, 2012. MDR isolates were defined as resistant to ≥3 antibiotic classes. RESULTS: A total of 368 children each contributed 1 isolate...
April 3, 2017: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/28357708/a-review-of-diagnostic-methods-for-invasive-fungal-diseases-challenges-and-perspectives
#5
REVIEW
Diego R Falci, Claudio M B Stadnik, Alessandro C Pasqualotto
Invasive fungal diseases are associated with a high morbidity and mortality, particularly in the context of immunosuppression. Diagnosis of invasive fungal diseases is usually complicated by factors such as poor clinical suspicion and unspecific clinical findings. Access to modern diagnostic tools is frequently limited in developing countries. Here, we describe five real-life clinical cases from a Brazilian tertiary hospital, in order to illustrate how to best select diagnostic tests in patients with different fungal infections...
March 29, 2017: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/28357707/comment-on-nu%C3%A3-o-solin%C3%A3-s-r-et-al-value-of-treating-all-stages-of-chronic-hepatitis-c-a-comprehensive-review-of-clinical-and-economic-evidence
#6
LETTER
Patrice Cacoub
No abstract text is available yet for this article.
March 29, 2017: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/28357706/the-burden-and-long-term-respiratory-morbidity-associated-with-respiratory-syncytial-virus-infection-in-early-childhood
#7
REVIEW
Brigitte Fauroux, Eric A F Simões, Paul A Checchia, Bosco Paes, Josep Figueras-Aloy, Paolo Manzoni, Louis Bont, Xavier Carbonell-Estrany
INTRODUCTION: The REGAL (RSV Evidence-a Geographical Archive of the Literature) series provide a comprehensive review of the published evidence in the field of respiratory syncytial virus (RSV) in Western countries over the last 20 years. The objective of this fifth publication was to determine the long-term respiratory morbidity associated with RSV lower respiratory tract infection (RSV LRTI) in early life. METHODS: A systematic review was undertaken for articles published between January 1, 1995 and December 31, 2015...
March 29, 2017: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/28357705/minocycline-for-the-treatment-of-multidrug-and-extensively-drug-resistant-a-baumannii-a-review
#8
REVIEW
Jennifer N Lashinsky, Oryan Henig, Jason M Pogue, Keith S Kaye
Acinetobacter baumannii can cause life-threatening nosocomial infections associated with high rates of morbidity and mortality. In recent years, the increasing number of infections due to extensively drug-resistant Acinetobacter with limited treatment options has resulted in a need for additional therapeutic agents, and a renaissance of older, neglected antimicrobials. This has led to an increased interest in the use of minocycline to treat these infections. Minocycline has been shown to overcome many resistance mechanisms affecting other tetracyclines in A...
March 29, 2017: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/28285420/fosfomycin-and-comparator-activity-against-select-enterobacteriaceae-pseudomonas-and-enterococcus-urinary-tract-infection-isolates-from-the-united-states-in-2012
#9
Tiffany R Keepers, Marcela Gomez, Chris Celeri, Kevin M Krause, Donald Biek, Ian Critchley
INTRODUCTION: Fosfomycin is a broad-spectrum cell wall active agent that inhibits the MurA enzyme involved in peptidoglycan synthesis and is FDA-approved for treatment of uncomplicated urinary tract infections (UTIs) caused by Escherichia coli and Enterococcus faecalis in women. Data regarding the susceptibility of recent UTI isolates to fosfomycin are limited. METHODS: This study compared the fosfomycin susceptibility of 658 US UTI isolates with susceptibility to ciprofloxacin, levofloxacin, nitrofurantoin, and trimethoprim/sulfamethoxazole (SXT)...
March 11, 2017: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/28265972/the-safety-and-economic-impact-of-cefazolin-versus-nafcillin-for-the-treatment-of-methicillin-susceptible-staphylococcus-aureus-bloodstream-infections
#10
Lauren K Flynt, Rachel M Kenney, Marcus J Zervos, Susan L Davis
INTRODUCTION: Anti-staphylococcal penicillins are generally accepted as first-line therapy for methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia, but their use may be limited by interstitial nephritis and acute kidney injury. Alternatives include first-generation cephalosporins including cefazolin. METHODS: We conducted a retrospective cohort study to compare adverse effects and clinical outcomes among patients with MSSA bacteremia treated with cefazolin or nafcillin...
March 6, 2017: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/28260148/anticipating-the-unpredictable-a-review-of-antimicrobial-stewardship-and-acinetobacter-infections
#11
REVIEW
Eric Wenzler, Debra A Goff, Romney Humphries, Ellie J C Goldstein
Acinetobacter remains one of the most challenging pathogens in the field of infectious diseases owing primarily to the uniqueness and multiplicity of its resistance mechanisms. This resistance often leads to devastatingly long delays in time to appropriate therapy and increased mortality for patients afflicted with Acinetobacter infections. Selecting appropriate empiric and definitive antibacterial therapy for Acinetobacter is further complicated by the lack of reliability in commercial antimicrobial susceptibility testing devices and limited breakpoint interpretations for available agents...
March 4, 2017: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/28258506/persistent-hepatitis-e-infection-in-a-patient-with-tuberous-sclerosis-complex-treated-with-everolimus-a-case-report
#12
Wobke E M van Dijk, Menno A M H Vergeer, Joop E Arends
INTRODUCTION: The incidence of hepatitis E (HEV) genotype 3 is rising in developed countries. HEV infections are usually self-limiting, but can become chronic in immunocompromised patients. This might lead to rapid fibrosis development even resulting in cirrhosis. Chronic HEV is mainly described in patients after solid-organ or hematological transplantations. We present the first case of HEV infection in a patient with tuberous sclerosis complex (TSC) treated with everolimus, a mammalian target of rapamycin (mTOR) inhibitor...
March 3, 2017: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/28160269/infections-in-cancer-patients-with-solid-tumors-a-review
#13
REVIEW
Kenneth V I Rolston
Solid tumors are much more common than hematologic malignancies. Although severe and prolonged neutropenia is uncommon, several factors increase the risk of infection in patients with solid tumors, and the presence of multiple risk factors in the same patient is not uncommon. These include obstruction (most often caused by progression of the tumor), disruption of natural anatomic barriers such as the skin and mucosal surfaces, and treatment-related factors such as chemotherapy, radiation, diagnostic and/or therapeutic surgical procedures, and the increasing use of medical devices such as various catheters, stents, and prostheses...
March 2017: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/28078655/single-dose-oritavancin-compared-to-standard-of-care-iv-antibiotics-for-acute-bacterial-skin-and-skin-structure-infection-in-the-outpatient-setting-a-retrospective-real-world-study
#14
Patrick J Anastasio, Pete Wolthoff, Annmarie Galli, Weihong Fan
INTRODUCTION: Cost-containment strategies are shifting the treatment of acute bacterial skin and skin structure infections (ABSSSI) from inpatient to outpatient settings. Current standard of care (SoC) requires multiple-dose regimens, which are associated with high hospitalization rates and high costs. Oritavancin, a new single-dose antibiotic for ABSSSI, may be suitable for outpatient therapy. This analysis evaluates the effectiveness, costs, and resource utilization of oritavancin vs...
March 2017: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/28070870/defining-the-risk-and-associated-morbidity-and-mortality-of-severe-respiratory-syncytial-virus-infection-among-infants-with-congenital-heart-disease
#15
REVIEW
Paul A Checchia, Bosco Paes, Louis Bont, Paolo Manzoni, Eric A F Simões, Brigitte Fauroux, Josep Figueras-Aloy, Xavier Carbonell-Estrany
INTRODUCTION: The REGAL (RSV Evidence-a Geographical Archive of the Literature) series provide a comprehensive review of the published evidence in the field of respiratory syncytial virus (RSV) in Western countries over the last 20 years. This fourth publication covers the risk and burden of RSV infection in infants with congenital heart disease (CHD). METHODS: A systematic review was undertaken for articles published between January 1, 1995 and December 31, 2015 across PubMed, Embase, The Cochrane Library, and Clinicaltrials...
March 2017: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/28039666/use-of-ceftaroline-fosamil-in-children-review-of-current-knowledge-and-its-application
#16
REVIEW
Juwon Yim, Leah M Molloy, Jason G Newland
Ceftaroline is a novel cephalosporin recently approved in children for treatment of acute bacterial skin and soft tissue infections and community-acquired bacterial pneumonia (CABP) caused by methicillin-resistant Staphylococcus aureus, Streptococcus pneumoniae and other susceptible bacteria. With a favorable tolerability profile and efficacy proven in pediatric patients and excellent in vitro activity against resistant Gram-positive and Gram-negative bacteria, ceftaroline may serve as a therapeutic option for polymicrobial infections, CABP caused by penicillin- and ceftriaxone-resistant S...
March 2017: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/28013453/pk-pd-target-attainment-with-ceftolozane-tazobactam-using-monte-carlo-simulation-in-patients-with-various-degrees-of-renal-function-including-augmented-renal-clearance-and-end-stage-renal-disease
#17
Alan J Xiao, Luzelena Caro, Myra W Popejoy, Jennifer A Huntington, Ravina Kullar
INTRODUCTION: Ceftolozane/tazobactam is an antibacterial agent with potent in vitro activity against Gram-negative pathogens, including many extended-spectrum β-lactamase-producing Enterobacteriaceae and drug-resistant Pseudomonas aeruginosa. Because ceftolozane/tazobactam is primarily excreted renally, appropriate dose adjustments are needed for patients with renal impairment. Monte Carlo simulations were used to determine the probability of pharmacokinetic/pharmacodynamic target attainment for patients with varying degrees of renal function, including augmented renal clearance (ARC) and end-stage renal disease (ESRD) with hemodialysis...
March 2017: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/27943223/in-vitro-activity-of-ceftolozane-tazobactam-alone-or-with-an-aminoglycoside-against-multi-drug-resistant-pseudomonas-aeruginosa-from-pediatric-cystic-fibrosis-patients
#18
Aimee M Dassner, Christina Sutherland, Jennifer Girotto, David P Nicolau
INTRODUCTION: Gram-negative multi-drug resistance is an emerging threat among pediatric patients with cystic fibrosis (CF). Ceftolozane/tazobactam (C/T) is an extended-spectrum cephalosporin/beta-lactamase inhibitor combination that has been shown to maintain activity against MDR P. aeruginosa isolates. The understanding of C/T effectiveness in pediatric patients is extremely limited. Minimum inhibitory concentration (MIC) testing and time-kill analyses were performed to better understand the antimicrobial susceptibility and potential role of C/T...
March 2017: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/27913975/clinical-impact-of-an-antibiotic-stewardship-program-at-a-children-s-hospital
#19
Brian R Lee, Jennifer L Goldman, Diana Yu, Angela L Myers, Leslie M Stach, Erin Hedican, Mary Anne Jackson, Jason G Newland
INTRODUCTION: Antibiotic stewardship programs (ASP) improve appropriate antibiotic use. Data are limited on the clinical benefit of ASPs in children's hospitals. This study's objective was to determine the impact of an ASP on length of stay (LOS) and readmission rate among patients admitted to children's hospitals. METHODS: Data from a prospective-audit-with-feedback ASP were used to examine the ASP review characteristics, including antibiotic(s) prescribed, clinical indication, recommendations made by the ASP, and agreement with recommendations...
March 2017: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/27910000/a-review-of-experimental-and-off-label-therapies-for-clostridium-difficile-infection
#20
REVIEW
Csaba Fehér, Alex Soriano, Josep Mensa
In spite of increased awareness and the efforts taken to optimize Clostridium difficile infection (CDI) management, with the limited number of currently available antibiotics for C. difficile the halt of this increasing epidemic remains out of reach. There are, however, close to 80 alternative treatment methods with controversial anti-clostridial efficacy or in experimental phase today. Indeed, some of these therapies are expected to become acknowledged members of the recommended anti-CDI arsenal within the next few years...
March 2017: Infectious Diseases and Therapy
journal
journal
48936
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"